 Zacks Investment Research upgraded shares of Clearside Biomedical NASDAQ:CLSD from a hold rating to a buy rating in a report published on Monday morning, Zacks.com reports. They currently have 2.25 price target on the stock. According to Zacks, Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding ... 